AIA
VVOS icon

Avalon Investment & Advisory’s Vivos Therapeutics VVOS Stock Holding History

Avalon Investment & Advisory’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-611
Closed -$34K – 342
2021
Q4 		$34K Sell
611
-12,562
-95% -$1.01M ﹤0.01% 300
2021
Q3 		$1.33M Buy
13,173
+5,583
+74% +$587K 0.03% 218
2021
Q2 		$939K Buy
7,590
+813
+12% +$132K 0.02% 247
2021
Q1 		$1.13M Buy
+6,777
New +$1.21M 0.03% 228

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Avalon Investment & Advisory's VVOS Position: Q1 2022 in Review

Avalon Investment & Advisory sold out of Vivos Therapeutics (VVOS) in Q1 2022, closing a stake of 611 shares — an estimated $34K sold.

Avalon Investment & Advisory first reported a position in VVOS in Q1 2021 and held it in 4 quarters. The position peaked at $1.33M in Q3 2021. 27 funds tracked by Wall St. Rank hold VVOS as of Q1 2022.

  • Avalon Investment & Advisory reported no remaining Vivos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Avalon Investment & Advisory sold 611 Vivos Therapeutics shares in Q1 2022, an estimated $34K.
  • Avalon Investment & Advisory first reported a position in Vivos Therapeutics in Q1 2021 and held it in 4 quarters.
  • Avalon Investment & Advisory's Vivos Therapeutics position peaked at $1.33M in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2022.

Based on Avalon Investment & Advisory's 13F filing for Q1 2022, filed 17 May 2022.